Journal of Clinical Trials
Open Access

Synthesis and in vitro evolution of benzimidazole based substituted purine as potential anticancer agents

International Conference on Clinical Trials

July 27-29, 2015 Orlando-FL, USA

Alka Sharma and Kamaldeep Paul

Posters-Accepted Abstracts: J Clin Trials

Abstract :

In medicinal chemistry, purine motifs have attracted a great deal of research interest due to their preponderance in pharmaceutically
indispensable compounds. Substituted purine especially 2, 6-disubstituted purine known to be very important medicinal and
pharmaceutical intermediate. benzimidazoles are categorized in the important pharmacophores and privileged sub-structures in
medicinal chemistry owing to their involvement as a key component for various biological activities. Therefore, introduction of
benzimidazole at C-6 position of 2, 6-dichloropurine is supposed to improve its activity and thereby selectivity. Due to individual
importance of purine and benzimidazole in living cells, we will present their synthesis as hybrids of benzimidazole at 6-position of
purine and evaluated in vitro anticancer activities. Thus, a series of purine/benzimidazole hybrids were prepared by introduction
of aromatic, aliphatic and heterocyclic moieties at the 2-position of purine to improve its potency and selectivity. Specifically,
these hybrids were substituted with different secondary amines to remarkably increase their activity beyond their normal scope.
Synthesized compounds were well characterized by 1H and 13C NMR as well as mass spectroscopy. The newly synthesized
compounds were screened for in vitro anticancer activities against 60 tumor cell lines panel assay. These results open up new
opportunities for other biological activities.